

Novel recurrently mutated genes in African American colon cancers


Kishore Guda^{a,b,c}, Martina L. Veigl^{b,c,1}, Vinay Varadan^{a,b,1}, Arman Nosrati^d, Lakshmeswari Ravi^d, James Lutterbaugh^d, Lydia Beard^d, James K. V. Willson^e, W. David Sedwick^{b,c,d}, Zhenghe John Wang^{b,f}, Neil Molyneaux^f, Alexander Miron^f, Mark D. Adams^g, Robert C. Elston^{b,h}, Sanford D. Markowitz^{b,c,d,i,2,3}, and Joseph E. Willis^{b,c,i,j,2}

^cDepartment of Medicine, ^fDepartment of Genetics and Genome Sciences, ^hDepartment of Epidemiology and Biostatistics, ^jDepartment of Pathology, ^aDivision of General Medical Sciences-Oncology, ^dDivision of Hematology and Oncology, ^bCase Comprehensive Cancer Center, and ⁱCase Medical Center, Case Western Reserve University, Cleveland, OH 44106; ^eHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390; and ^gJ. Craig Venter Institute, La Jolla, CA 92037


“....Mutations in a set of 15 of these genes appear to be strongly preferentially associated with CRCs arising in AA versus Caucasian individuals, suggesting an important difference in the mutational landscapes of CRCs arising in different ethnic groups.”

Guda et al., Proc. Natl. Acad. Sci. 112:1149, 2015

Poorer outcome for colorectal cancer associated with mutations that are more common in African Americans




Stage I - III (Months)	0	90	180
M- No.	39	12	2
M+ No.	27	4	1



Stage III (Months)	0	90	180
M- No.	18	10	2
M+ No.	15	3	1

***Continuing to
strongly support
investigator-initiated
research, training,
and other research
activities***



Number of R01s/R35s Awarded




	FY13	FY14	FY15	FY16
Unsolicited R01s	582	578	623	650
R35s	--	--	43	35
Total Unsolicited	582	578	666	685

RFA R01s	29	51	12	45
Total Solicited and Unsolicited	611	629	678	730

Changes in RPG pool: FY12-FY16 and beyond



Changes in RPG pool: FY12-FY16 and beyond



Blue Ribbon Panel Recommendations Funding vs. NCI Fiscal Year Funding


BRP: THE RESEARCH EXPRESS LANE

Experts identified areas poised for success—ripe for making near-term advances—with potential for big impact if additional Moonshot resources are made available.


● RESEARCH EXPRESS LANE



RESEARCH AREA




POISED FOR ACCELERATION



Cancer Funding in 21st Century Cures Act

- The cancer research portion is now named the Beau Biden Cancer Moonshot Initiative
- \$1.8 billion over 7 years, with \$300 million for FY17
- *To support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, research that has the potential to transform the scientific field that has inherently higher risk, and that seeks to address major challenges associated with cancer.”*

NCI BUDGET 2005 – 2015: A PERIOD OF LEVEL BUDGETS & PROGRESSIVELY DECREASING PURCHASING POWER FY 2016 & 2017: AN ENCOURAGING TREND



----- The dashed line at approximately \$3.3 billion indicates that the inflation-adjusted FY 2017 proposed budget is similar to the FY 2000 budget



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol